NCCN Guidelines® Insights - Survivorship, Version 1.2021
The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor’s complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment; recommendations to help promote healthful lifestyle behaviors, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes the recommendations regarding employment and return to work for cancer survivors that were added in the 2021 version of the NCCN Guidelines.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Survivorship
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Survivorship
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Crystal S. Denlinger, MD, Panel Chair, has disclosed serving as a scientific advisor for BeiGene, Bristol-Myers Squibb Company, Exelixis Inc., Merck & Co., Inc., and Zymeworks, and receiving honoraria from Eli Lilly and Company and Taiho Parmaceuticals Co., Ltd.
Tara Sanft, MD, Panel Vice Chair, has disclosed no relevant financial relationships.
Shannon M. Ansbaugh, Patient Advocate, has disclosed no relevant financial relationships.
Gregory Broderick, MD, Panel Member, has disclosed receiving consulting fees from Endo Pharmaceuticals Inc.
Andrew Day, MD, MPH, Panel Member, has disclosed no relevant financial relationships.
Wendy Demark-Wahnefried, PhD, RD, Panel Member, has disclosed no relevant financial relationships.
Norah Lynn Henry, MD, PhD, Panel Member, has disclosed no relevant financial relationships.
Melissa Hudson, MD, Panel Member, has disclosed no relevant financial relationships.
Lindsay Peterson, MD, Panel Member, has disclosed no relevant financial relationships.
Lidia Schapira, MD, Panel Member, has disclosed no relevant financial relationships.
Karen L. Syrjala, PhD, Panel Member, has disclosed no relevant financial relationships.
Amye Tevaarwerk, MD, Panel Member, has disclosed no relevant financial relationships.
Nicole R. McMillian, MS, CHES, Guidelines Coordinator, NCCN, has disclosed no relevant financial relationships.
Deborah A. Freedman-Cass, PhD, Manager, Licensed Clinical Content, NCCN, has disclosed no relevant financial relationships.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-21-009-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until June 10, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation